Abstract
Severe adverse events (SAE) and late hematological malignancies have been reported after PBSC donation. No prospective data on incidence and risk factors have been available for family donors so far. The Japan Society for Hematopoietic Cell Transplantation (JSHCT) introduced therefore in 2000 a mandatory registration system. It defined standards for donor eligibility and asked harvest centers to report any SAE immediately. All donors were examined at day 30 and were to be contacted once each year for a period of 5 years. Acute SAEs within day 30 were reported from 47/3264 donations (1.44%) with 14 events considered as unexpected and severe (0.58%). No donor died within 30 days. Late SAEs were reported from 39/1708 donors (2.3%). The incidence of acute SAEs was significantly higher among donors not matching the JSHCT standards (P=0.0023). Late hematological malignancies in PBSC donors were not different compared with a retrospective cohort of BM donors (N:1/1708 vs N:2/5921; P=0.53). In conclusion, acute and late SAEs do occur in PBSC donors at relatively low frequency but risk factors can be defined.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Russell NH, Hunter A, Rogers S, Hanley J, Anderson D . Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet 1993; 341: 1482.
Dreger P, Suttorp M, Haferlach T, Loffler H, Schmitz N, Schroyens W . Allogeneic granulocyte colony stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 1993; 81: 1404–1407.
Weaver CH, Buckner CD, Longin K, Appelbaum FR, Rowley S, Lilleby K et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 1993; 82: 1981–1984.
Tanaka J, Imamura M, Zhu X, Kobayashi S, Imai K, Hashino S et al. Potential benefit of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood stem cells for allogeneic transplantation. Blood 1994; 84: 3595–3596.
Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655–1658.
Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR et al. Blood and Marrow Clinical Trials Network. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487–1496.
Schmitz N, Dreger P, Suttorp M, Suttorp M, Rohwedder EB, Harferlach T et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by Filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666–1672.
Schmitz N, Bacigalupo A, Hansenclever D, Nagler A, Gluckman E, Clark P et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995–1003.
Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomized trial. Lancet 2000; 355: 1231–1237.
Friedrichs B, Tichelli A, Bacigalupo A, Russellet NH, Ruutu T, Shapira MY et al. Long-term outcome and late effects in patients transplanted with mobilized blood or bone marrow: a randomized trial. Lancet Oncol 2010; 11: 331–338.
Anderlini P, Korbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90: 903–908.
Confer DL, Stroncek DF . Bone marrow and peripheral blood stem cell donors Thomas ED, Blume KG, Forman SJ (eds) In. Hematopoietic Cell Transplantation. Blackwell Science, Inc: MA, USA, 421–430 1999.
Baker D, Durrant S . Fatal stroke following filgrastim mobilization of PBPC for allogeneic transplantation. Bone Marrow Transplant 1999; 23 (Suppl 1): s236.
Adler BK, Salzman DE, Carabasl MH, Vaughan WP, Reddy VVB, Prchal JT . Fetal sickle cell crisis after granulocyte colony-stimulating factor administratio. Blood 2001; 97: 3313–3314.
de Azevedo AM, Tabak DG . Life-threatening capillary leak syndrome after G-CSF mobilization and collection of peripheral blood progenitor cells for allogeneic transplantation. Bone Marrow Transplant 2001; 28: 311–312.
Becker PS, Wagle M, Matous S, Swanson RS, Piban G, Lowry PA et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): Occurrence in allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997; 3: 45–49.
Falzetti F, Aversa F, Minelli O, Tabilio A . Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999; 353: 555.
Halter JP, van Walraven SM, Worel N, Bengtsson M, Hagglund H, Nicoloso de Faveri G et al. Allogeneic hematopoietic stem cell donation: standardized assessment of donor outcome data. A WBMT consensus document. Bone Marrow Transplant, (advance online publication) 2012; 48: 220–225.
Halter JP, Kodera Y, Ispizua AU, Ispizua U, Greinix HT, Schmitz N et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009; 94: 94–101.
Makita K, Ohta K, Mugitani A, Hagihara K, Ohta T, Yamane T et al. Acute myelogeneous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 2004; 33: 661–665.
Sakamaki S, Takamoto S, Shibata H . Complications of marrow harvesting for transplantation. Jpn J Clin Hematol 1994; 35: 29–35 in Japanese.
Murata M, Harada M, Kato S, Takahashi S, Ogawa H, Okamoto S et al. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors. Bone Marrow Transplant 1999; 24: 1065–1071.
Cleaver SA, Goldman JM . Use of G-CSF to mobilize PBSC in normal healthy donors-an international survey. Bone Marrow Transplant 1998; 21 (Suppl 3): s29–s31.
Anderlini P, Przepiorka D, Seong D, Miller P, Sundberg J, Lichtiger B et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of changes for the procedures. Transfusion 1996; 36: 590–595.
Hasenclever D, Sextro M . Safety of AlloPBSCT donors: Biochemical considerations on monitoring long term risks. Bone Marrow Transplant 1996; 17 (Suppl 2): s28–s31.
De la Rubia J, de Arriba F, Arbona C, Pascual MJ, Zamora C, Insunza A et al. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica 2008; 93: 735–740.
Cavallaro AM, Lilleby K, Majolino I, Storb R, Appelbaum FR, Rowley SD et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000; 25: 85–89.
Canales MA, Arrieta R, Gomez-Rioja R, Diez J, Jimenez-Yuste V, Hernandez-Navarro F . Induction of a hypercoagulability state and endotherial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors. J Hematother Stem Cell Res 2002; 11: 675–681.
Topcuoglu P, Arat M, Dalva K, Ozcan M . Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors. Bone Marrow Transplant 2004; 33: 171–175.
Karadogan C, Karadogan I, Bilgin AU, Under L . rHuG-CSF increases the platelet-neutrophil complex formation and neutrophil adhesion molecule expression in volunteer granulocyte and stem cell apheresis donors. Apher Dial 2006; 10: 180–186.
Nagler A, Korenstein-Ilan A, Amiel A, Avini L . Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004; 32: 122–130.
Hirsch B, Oseth L, Cain M, Trader E, Pulkrabek S, Lindgren B et al. Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors. Blood 2011; 118: 2602–2608.
Avalos BR, Lazaryan A, Copelan EA . Can G-CSF cause leukemia in hematopoietic stem cell donors? Biol Blood Marrow Transplant 2011; 17: 1739–1746.
Anderlini P, Przepiorka D, Champlin R, Korbling M . Biological and clinical effects of granulocyte colony stimulating factor in normal individuals. Blood 1996; 88: 2819–2825.
Ridker PM, Glynn RJ, Hennekens CH . C-reactive protein adds the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007–2011.
Margolis D, Dincer A, Anderson L, Moraski L, Casper J, Gottshall J . Serious adverse events in peripheral blood progenitor cell mobilization: A trigger for changing the donation process. Blood 2001; 98: 178a.
World Health Organization. WHO guiding principles on human cells, tissue and organ transplantation. Transplantation 2010; 90: 229–233.
Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD et al. Adverse events among 2408 unrelated donors of peripheral blood stem cell: results of a prospective trial from National Marrow Donor Program. Blood 2009; 113: 3604–3611.
Holing K, Kramer M, Kroschinsky F, Bornhauser M, Menbling T, Schmidt AH et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3929 donors. Blood 2009; 114: 3757–3763.
Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the research on adverse drug events and reports (RADAR) project. Br J Haematol 2006; 135: 642–650.
Pentz RD . Healthy sibling donation of G-CSF primed stem cells: Call for research. Pediatr Blood Cancer 2006; 46: 407–408.
Acknowledgements
We thank R Kodera, K Kawai, T Shimizu and Y Yamada (EPS Co.) for their generous assistance in the course of the survey. The study was partially supported by Health and Labor Sciences Research Grants, Research on Tissue Engineering, Ministry of Health, Labor and Welfare, Japan. JH and AG were in part supported by the Swiss National Foundation grant NRP 63.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Author Contributions
YK, KY and MH designed the study and wrote the paper. YM, HD, SA, MI, KK, SK and MT collected and organized the data. YK, RT, SS, SWK, KN, MH, KM and RS supervised the process of data collection. NH, MF and AK performed the statistical analysis. JH, NS, DN and AG consulted with the study concept and reviewed the results.
Supplementary Information accompanies this paper on Bone Marrow Transplantation website
Supplementary information
Rights and permissions
About this article
Cite this article
Kodera, Y., Yamamoto, K., Harada, M. et al. PBSC collection from family donors in Japan: a prospective survey. Bone Marrow Transplant 49, 195–200 (2014). https://doi.org/10.1038/bmt.2013.147
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2013.147
Keywords
This article is cited by
-
Long-term follow-up of cancer and catastrophic diseases in hematopoietic stem cell donors: a comprehensive matched cohort study
Bone Marrow Transplantation (2024)
-
Severe short-term adverse events in related bone marrow or peripheral blood stem cell donors
International Journal of Hematology (2023)
-
Basic characteristics and safety of donation in related and unrelated haematopoietic progenitor cell donors – first 10 years of prospective donor follow-up of Swiss donors
Bone Marrow Transplantation (2022)
-
Cancer incidence in healthy Swedish peripheral blood stem cell donors
Bone Marrow Transplantation (2022)
-
Syngeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a propensity score-matched analysis
Blood Cancer Journal (2021)